The Rising Occurrence of Injectable Drugs
The increasing prevalence of chronic diseases like cancer, diabetes, cardiovascular diseases and others are among the major factors responsible for the growth of the Brazil serum Drugs market. Cancer is one of the leading causes of death in Brazil and the occurrence of cancer has been on the rise over the past few decades. According to the National Cancer Institute, an estimated 600,000 new cancer cases were recorded in 2018 in Brazil. The institute projected that over 190,000 people will die due to cancer in 2022. Similarly, diabetes is also highly prevalent in the country, with nearly 14 million Brazilians suffering from the disease as of 2021. Moreover, cardiovascular diseases have also emerged as a major public health concern, accounting for over 30% of all deaths annually in the country. The rising cases of chronic and life-threatening diseases have significantly driven up the demand for high-potency and targeted serum Drugs in the country for disease treatment and management.
Hospitals Remain the Injectable Drugs
Hospitals currently account for the largest end-users of Injectable Drugs Market Growth in Brazil. The high usage of injectable medications in both inpatient and outpatient hospital settings is a major factor why hospitals dominate the end-user segment. Most complex injectable drug therapies are mostly administered in hospitals under medical supervision. Moreover, the rising trend of complex drug therapies and clinical trial activities in hospitals have also facilitated the growth of the hospitals segment. However, the ambulatory care center segment is expected to witness fastest growth during the forecast period owing to the shifting healthcare trends towards outpatient care and expansion of ambulatory surgical centers in the country.
Generic Injectables Lead Market Demand
The generic serum Drugs segment currently holds the majority of the market share owing to their affordability and availability in Brazil. As patented drugs lose their exclusivity, generic drug manufacturers quickly release biosimilar versions which significantly drives down treatment costs for patients. This has boosted uptake of generic injectables among healthcare facilities and patients for cost-effective treatment of chronic conditions. On the other hand, the biosimilars segment is projected to exhibit strong growth rates over the coming years, mainly attributed to patent expiries of major biologic drugs and introduction of more biosimilar drugs in the market.
Home Healthcare Gaining Traction
The Brazil serum Drugs market is witnessing the growing popularity of home healthcare services which involves stable and knowledgeable clinical professionals offering healthcare services at patients’ homes. The rising geriatric population opting for home healthcare, complex medical conditions making hospital stay difficult, and surge of specialized home healthcare service providers are some key factors fostering the expansion of home healthcare in Brazil. This trend is expected to have a positive influence on the uptake of self-serum Drugs for administering chronic treatment regimens at home with medical supervision. Several pharma companies are focusing on developing suitable self-administrable drug delivery systems eyeing opportunities in Brazil’s expanding home healthcare space.
Market Players Emphasizing Capacity Enhancements
Brazil represents one of the most lucrative markets for injectable drug sales in Latin America due to the availability of national public healthcare coverage and pharmaceutical patent laws. Brazil major pharmaceutical companies like Aché Laboratórios Farmacêuticos, Hypera Pharma, Laboratório Pasteur and ECZACIBASI-MONROL are actively expanding their manufacturing facilities to boost domestic production capabilities. Meanwhile, international pharma giants including Pfizer, Roche, Sanofi, Novartis and GlaxoSmithKline are strengthening their Brazilian operations through new production lines, R&D collaborations and mergers & acquisitions. As the demand for serum Drugs surges on account of rising prevalence of chronic diseases, market players are strategically scaling up their manufacturing capacities with latest technologies to ensure consistent supply and gain a larger market share.
The demand for serum Drugs in Brazil is experiencing robust growth driven by rising chronic disease burden, expansion of healthcare infrastructure, increasing healthcare expenditure and availability of public universal healthcare coverage. Hospitals currently dominate the end-user segment but ambulatory care centers are projected to accelerate in the forthcoming years. Generic injectables continue to lead market demand owing to affordability while biosimilars also offer lucrative opportunities. Manufacturers are augmenting production capacities and investing in technologically advanced facilities to reap gains in Brazil’s high-potential serum Drugs market.
Get More Insights on Injectable Drugs Market
For Better Understanding, choose your preferred language-
About Author-
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
